Aspen Technology (NASDAQ:AZPN) Issues FY25 Earnings Guidance
by Amy Steele · The Cerbat GemAspen Technology (NASDAQ:AZPN – Get Free Report) updated its FY25 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $7.52 for the period, compared to the consensus estimate of $7.46. The company issued revenue guidance of $1.19 billion, compared to the consensus revenue estimate of $1.19 billion.
Aspen Technology Stock Up 1.7 %
NASDAQ:AZPN traded up $3.92 during trading hours on Monday, hitting $237.59. 209,740 shares of the company’s stock traded hands, compared to its average volume of 202,025. The firm has a market cap of $15.03 billion, a P/E ratio of -1,482.25, a P/E/G ratio of 2.74 and a beta of 0.76. Aspen Technology has a 52 week low of $162.26 and a 52 week high of $244.85. The business’s fifty day simple moving average is $232.68 and its two-hundred day simple moving average is $212.65.
Aspen Technology (NASDAQ:AZPN – Get Free Report) last posted its earnings results on Tuesday, August 6th. The technology company reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.49. Aspen Technology had a positive return on equity of 2.96% and a negative net margin of 0.87%. The firm had revenue of $342.91 million for the quarter, compared to the consensus estimate of $319.10 million. During the same quarter in the prior year, the business earned $1.87 EPS. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts expect that Aspen Technology will post 6.53 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on AZPN shares. Loop Capital upped their price objective on Aspen Technology from $204.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Bank of America upped their target price on Aspen Technology from $225.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Robert W. Baird upped their price objective on Aspen Technology from $230.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler boosted their target price on shares of Aspen Technology from $200.00 to $217.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Aspen Technology currently has an average rating of “Moderate Buy” and an average target price of $248.40.
Get Our Latest Research Report on AZPN
Insider Activity
In other Aspen Technology news, Director Jr. Robert M. Whelan sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $219.10, for a total value of $219,100.00. Following the sale, the director now directly owns 8,540 shares of the company’s stock, valued at approximately $1,871,114. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.00% of the company’s stock.
Aspen Technology Company Profile
Aspen Technology, Inc provides industrial software that focuses on helping customers in asset-intensive industries worldwide. The company’s solutions address complex environments where it is critical to optimize the asset design, operation, and maintenance lifecycle. Its software is used in performance engineering, modeling and design, supply chain management, predictive and prescriptive maintenance, digital grid management, and industrial data management.
Featured Articles
- Five stocks we like better than Aspen Technology
- 3 Small Caps With Big Return Potential
- Intel: Is Now the Time to Be Brave?
- Where to Find Earnings Call Transcripts
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- The 3 Best Fintech Stocks to Buy Now
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?